NCT04416178
Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 20 versions: 20 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 10 words Show 4 more changesShow less
- Primary endpoints: details revised at 1 of 2 entries
- Study completion pushed from Dec 2026 to May 2027
- Study description revised
- Site details revised
- Minor Site contact updatedv19
- Notable Eligibility criteria expanded, about 54 words
- Trial arms changed: 2 → 3
Notable Trial status: Active, Not Recruiting to Recruitingv17 Show 5 more changesShow less
- Eligibility criteria expanded, about 63 words
- Enrollment target: 300 to 352
- Study completion date: Dec 2025 to Dec 2026
- Study description expanded, about 23 words
- Site details revised
- Minor Trial status: Completed to Active, Not Recruiting
- Study completion date: Mar 26, 2024 to Dec 2025
- Study description expanded, about 24 words
Show 14 earlier versionsHide 14 earlier versions
- Minor Trial status: Active, Not Recruiting to Completed
- Primary and study completion dates changed from estimate of Jun 2024 to Mar 26, 2024
- Minor Primary and study completion dates: Feb 2024 to Jun 2024v14
- Minor Primary and study completion dates: Sep 2023 to Feb 2024v13
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised
- Notable Primary and study completion dates: Sep 2022 to Sep 2023v11
- Minor Enrollment target: 312 to 300
- Study description shortened, about 47 words
- Minor Start date changed from estimate of Jan 2021 to Dec 17, 2020v9
Notable Trial status: Suspended to Recruitingv8 Show 6 more changesShow less
- Primary and study completion dates pushed to Sep 2022
- Start date: Nov 2020 to Jan 2021
- Enrollment target: 300 to 312
- Study description expanded, about 71 words
- Site details revised
- Study title revised
- Minor Start date: Oct 2020 to Nov 2020v7
- Minor Start date: Sep 2020 to Oct 2020v6
- Minor Start date: Aug 2020 to Sep 2020v5
- Minor Start date: Jul 2020 to Aug 2020v4
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: Temporary Enrollment Hold due to COVID-19
- Start date: Jun 2020 to Jul 2020
- Site details revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
Parent of child with HbSS, HbS/ β0thalassemia, β+ thalassemia or HbSC aged 12 months to 18 years at study initiation, irrespective of clinical severity or patient aged 13-18 with aforementioned SCD genotype.
Adult Patient with or Parent of child with HbSS, HbS/ β0thalassemia, β+ thalassemia or HbSC aged 12 months to 18 years at study initiation, irrespective of clinical severity or patient aged 16-18 with aforementioned SCD genotype whose parent provides verbal informed consent for focus group participation.
Parent of child with HbSS, HbS/ β0thalassemia, β+ thalassemia or HbSC aged 12 months to 18 years at study initiation, irrespective of clinical severity or patient aged 13 and up with aforementioned SCD genotype.
Sites
1 site in 1 country
- St. Jude Children's Research HospitalMemphis, Tennessee, United States